Companies › Arctic Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 2; Neurology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Caficrestat (NPI-001) Aldose reductase inhibitor | AKR1B1 | Phase 2 | Hereditary Cystatin C Amyloid Angiopathy (HCCAA) | Dec 2026 |
| NPI-001 (AT-001) | – | Phase 2 | Alzheimer´s Disease | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07716865 | Caficrestat (NPI-001) | Phase 2 | Hereditary Cystatin C Amyloid Angiopathy (HCCAA) | Neurology | Dec 2026 |
| NCT07741526 | NPI-001 (AT-001) | Phase 2 | Alzheimer´s Disease | Neurology | Apr 2027 |
Dasher Neuroscience ThromBio Appello Pharmaceuticals PhenoNet Glycomine
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.